AgenT


AgenT is developing the first blood diagnosis to detect Alzheimer's disease early, up to 20 years before irreversible symptoms appear. Their mission is to enable early detection through a multiomics platform that combines machine learning and biomarkers signals, aiming to prevent or stop the progression of Alzheimer's. They collaborate with leading academic medical centers and are engaged in clinical research and partnerships to validate their innovative diagnostic approach.

Industries

biotechnology
health-care
health-diagnostics
life-science
neuroscience-e37a

Nr. of Employees

small (1-50)

AgenT

Paris, Ile-de-France, France, Europe


Products

Blood-based multiomics diagnostic test for early Alzheimer's detection

A diagnostic approach that analyses plasma proteins and metabolites and applies machine learning to detect Alzheimer's-associated biomarker patterns across asymptomatic, prodromal and dementia stages from routine blood draws.


Services

Retrospective multi-center biomarker validation studies

Design and execution of retrospective, multi-site studies to validate multiomics biomarkers in archived plasma samples across disease stages.

Collaborative research partnerships and sample access

Partnership formation to enable shared research projects, access to clinical cohorts, and joint analytical workflows for early-detection research.

Expertise Areas

  • Clinical trial management for biomarker studies
  • Biomarker discovery and translation
  • Proteomics
  • Metabolomics
  • Show More (6)

Key Technologies

  • Proteomics (plasma protein profiling)
  • Metabolomics (plasma metabolite profiling)
  • Machine learning and AI for pattern recognition
  • Multiomics integration
  • Show More (4)

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.